Two patients from the first cohort developed alternative diagnoses during follow-up (1 each with neuromyelitis optica spectrum disorder [NMOSD] and myelin oligodendrocyte glycoprotein antibody-associated disorder [MOGAD]) and were excluded. This evidence concerns the gene OMG and neuromyelitis optica.